Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Iqvia Holdings Inc.
Headquarters: Danbury, CT, United States of America
Website: http://www.iqvia.com
Year Founded: 2016
Status: Public
Industry Sector: CommercialServices
CEO: Ari Bousbib, MBA
Number Of Employees: 88,000
Enterprise Value: $48,675,934,000
PE Ratio: 23.26
Exchange/Ticker 1: NYSE:IQV
Exchange/Ticker 2: N/A
Latest Market Cap: $30,744,047,616
BioCentury | Mar 7, 2025
Management Tracks
Abbas Kazimi succeeds Jeb Keiper as CEO of Nimbus
Plus: Jon Garay Alonso named CFO of Almirall, and updates from Certara and Immunai
BioCentury | Feb 6, 2025
Market Access
U.S. biosimilars held back by more than just reimbursement
Iqvia’s latest report cites regulatory requirements, investment costs, and lack of market acceptance and predictability
BioCentury | Oct 11, 2024
Management Tracks
Flagship takes on a third managing partner
Plus: New CEOs at Wheeler, Abalos, Oncovita, Syneos and Calluna, and updates from Phase, Ziphius and more
BioCentury | Aug 30, 2024
Market Access
Payers’ speed bumps harm patients — and are likely to get worse
Over 75% of cancer drug prescriptions are initially rejected
BioCentury | May 22, 2024
Market Access
What’s behind CVS’s changing adalimumab strategy
Company opens the door to biosimilars on its major formularies while partnering with AbbVie on a co-branded Humira
BioCentury | Nov 17, 2023
Product Development
Reimagining clinical trials at ARPA-H
New agency initiative seeks to enable nearly all eligible U.S. patients to enroll in a trial close to home
BioCentury | Nov 3, 2023
Product Development
Tokenization: lowering barriers to evidence generation
Linking data sources via tokenization will change the way clinical data are collected and interpreted
BioCentury | May 4, 2023
Market Access
IQVia: 53% of retail prescriptions costing over $250 are abandoned
Average out-of-pocket costs may not be increasing much, but the long tail still led to millions of abandoned prescriptions in 2022
BioCentury | Jan 6, 2023
Data Byte
CMS: retail drug spend remains small fraction of total health spend
Increase in total national health expenditure is once again primarily driven by hospital care and physician and clinical services
BioCentury | Nov 16, 2022
Management Tracks
Bungay becomes CEO at Imophoron, Garzoni transitions to CSO
Plus: Tracy named CTO at Code, and updates from ConcertAI, Lucy, Trevi and more
Items per page:
1 - 10 of 62